Illumina (ILMN) Tops Q4 EPS by 12c, FY EPS Guidance Misses Consensus

Illumina (NASDAQ: ILMN) reported Q4 EPS of $1.22, $0.12 better than the analyst estimate of $1.10. Revenue for the quarter came in at $953 million versus the consensus estimate of $898.38 million.

GUIDANCE:

Illumina sees FY2021 EPS of $5.10-$5.35, versus the consensus of $6.11.

• For fiscal 2021, the company expects year-over-year revenue growth in the range of 17% to 20%, and expects GAAP earnings per diluted share of $4.76 to $5.01 and non-GAAP earnings per diluted share of $5.10 to $5.35. This guidance excludes the potential impact from the pending acquisition of GRAIL, which we expect to close in the second half of 2021.

For earnings history and earnings-related data on Illumina (ILMN) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half